Elanco Animal Health reported a 10% revenue increase in Q2 2026, driven by strong demand for new pet health products like Zenrelia and Credelio Quattro. The company raised its full-year 2026 guidance, expecting revenue between $5.09 billion and $5.14 billion, adjusted EBITDA up to $1.035 billion, and adjusted EPS of $1.10 to $1.16. Improved margins and a reduced net leverage ratio to 3.1x highlight operational efficiency and financial strength. Elanco's innovation strategy and market share gains position it well for sustained growth in the animal health industry.
Blue Owl Capital is still rated a Buy due to improved investor sentiment, stable credit quality, and supportive valuations, even amid macroeconomic and interest rate challenges. Redemption pressures are easing as loan repayments cover redemption requ...
Blue Owl Technology Finance (OTF) is rated Hold due to ongoing net asset value (NAV) decline, disappointing net investment income, and higher volatility compared to its business development company peers. Its current base dividend distribution is not...
Tesla has registered a local entity in Vietnam, signaling plans to enter the country's rapidly growing electric vehicle market. Vietnam's EV market is led by VinFast, which holds 92% market share and benefits from a strong local ecosystem including c...
A trader using the wallet 0xc3ed was liquidated four times within 14 hours on Bitcoin short positions as the price surged above $85,000, resulting in a $32.5 million loss. Previously, the trader had made $9.26 million in profits from successful long ...
Noah Holdings, a wealth management firm serving global Chinese families, held its 2026 Global Investor Summit in Hong Kong, focusing on AI-driven industry transformation and long-term wealth planning. The company combines its global investment networ...
